1
|
Natesan R, Dykstra AB, Banerjee A, Agrawal NJ. Heterogeneity in Disulfide Bond Reduction in IgG1 Antibodies Is Governed by Solvent Accessibility of the Cysteines. Antibodies (Basel) 2023; 12:83. [PMID: 38131805 PMCID: PMC10741012 DOI: 10.3390/antib12040083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 11/22/2023] [Accepted: 12/01/2023] [Indexed: 12/23/2023] Open
Abstract
We studied unpaired cysteine levels and disulfide bond susceptibility in four different γ-immunoglobulin antibodies using liquid chromatography-mass spectrometry. Our choice of differential alkylating agents ensures that the differential peaks are non-overlapping, thus allowing us to accurately quantify free cysteine levels. For each cysteine residue, we observed no more than 5% to be unpaired, and the free cysteine levels across antibodies were slightly higher in those containing lambda light chains. Interchain and hinge residues were highly susceptible to reducing stresses and showed a 100-1000-fold higher rate of reduction compared to intrachain cysteines. Estimations of the solvent-accessible surface for individual cysteines in IgG1, using an implicit all-atom molecular dynamics simulation, show that interchain and hinge cysteines have >1000-fold higher solvent accessibility compared to intrachain cysteines. Further analyses show that solvent accessibility and the rate of reduction are linearly correlated. Our work clearly establishes the fact that a cysteine's accessibility to the surrounding solvent is one of the primary determinants of its disulfide bond stability.
Collapse
Affiliation(s)
- Ramakrishnan Natesan
- Amgen Inc., Process Development, 360 Binney St., Cambridge, MA 02141, USA; (R.N.); (A.B.)
| | | | - Akash Banerjee
- Amgen Inc., Process Development, 360 Binney St., Cambridge, MA 02141, USA; (R.N.); (A.B.)
| | - Neeraj J. Agrawal
- Amgen Inc., Process Development, 360 Binney St., Cambridge, MA 02141, USA; (R.N.); (A.B.)
| |
Collapse
|
2
|
Gaikwad M, Richter F, Götz R, Dörrbaum A, Schumacher L, Tonillo J, Frech C, Kellner R, Hopf C. Site-Specific Structural Changes in Long-Term-Stressed Monoclonal Antibody Revealed with DEPC Covalent-Labeling and Quantitative Mass Spectrometry. Pharmaceuticals (Basel) 2023; 16:1418. [PMID: 37895889 PMCID: PMC10609731 DOI: 10.3390/ph16101418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 09/14/2023] [Accepted: 09/25/2023] [Indexed: 10/29/2023] Open
Abstract
Studies of structural changes in mAbs under forced stress and storage conditions are essential for the recognition of degradation hotspots, which can be further remodeled to improve the stability of the respective protein. Herein, we used diethyl pyrocarbonate (DEPC)-based covalent labeling mass spectrometry (CL-MS) to assess structural changes in a model mAb (SILuMAb). Structural changes in the heat-stressed mAb samples were confirmed at specific amino acid positions from the DEPC label mass seen in the fragment ion mass spectrum. The degree of structural change was also quantified by increased or decreased DEPC labeling at specific sites; an increase or decrease indicated an unfolded or aggregated state of the mAb, respectively. Strikingly, for heat-stressed SILuMAb samples, an aggregation-prone area was identified in the CDR region. In the case of longterm stress, the structural consequences for SILuMAb samples stored for up to two years at 2-8 °C were studied with SEC-UV and DEPC-based CL-MS. While SEC-UV analysis only indicated fragmentation of SILuMAb, DEPC-based CL-MS analysis further pinpointed the finding to structural disturbances of disulfide bonds at specific cysteines. This emphasized the utility of DEPC CL-MS for studying disulfide rearrangement. Taken together, our data suggests that DEPC CL-MS can complement more technically challenging methods in the evaluation of the structural stability of mAbs.
Collapse
Affiliation(s)
- Manasi Gaikwad
- Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany; (M.G.); (F.R.)
| | - Florian Richter
- Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany; (M.G.); (F.R.)
| | - Rabea Götz
- Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany; (M.G.); (F.R.)
| | - Aline Dörrbaum
- Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany; (M.G.); (F.R.)
| | - Lena Schumacher
- Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany; (M.G.); (F.R.)
| | - Jason Tonillo
- Merck Healthcare KGaA, ADCs & Targeted NBE Therapeutics, Frankfurter Str. 250, 64293 Darmstadt, Germany
| | - Christian Frech
- Faculty of Biotechnology, Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany
| | - Roland Kellner
- Merck Healthcare KGaA, ADCs & Targeted NBE Therapeutics, Frankfurter Str. 250, 64293 Darmstadt, Germany
| | - Carsten Hopf
- Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany; (M.G.); (F.R.)
- Faculty of Biotechnology, Mannheim University of Applied Sciences, Paul-Wittsack-Str. 10, 68163 Mannheim, Germany
- Medical Faculty, Heidelberg University, 69117 Heidelberg, Germany
| |
Collapse
|
3
|
Mieczkowski C, Zhang X, Lee D, Nguyen K, Lv W, Wang Y, Zhang Y, Way J, Gries JM. Blueprint for antibody biologics developability. MAbs 2023; 15:2185924. [PMID: 36880643 PMCID: PMC10012935 DOI: 10.1080/19420862.2023.2185924] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Abstract
Large-molecule antibody biologics have revolutionized medicine owing to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles, and amenability to versatile engineering. In this review, we focus on preclinical antibody developability, including its definition, scope, and key activities from hit to lead optimization and selection. This includes generation, computational and in silico approaches, molecular engineering, production, analytical and biophysical characterization, stability and forced degradation studies, and process and formulation assessments. More recently, it is apparent these activities not only affect lead selection and manufacturability, but ultimately correlate with clinical progression and success. Emerging developability workflows and strategies are explored as part of a blueprint for developability success that includes an overview of the four major molecular properties that affect all developability outcomes: 1) conformational, 2) chemical, 3) colloidal, and 4) other interactions. We also examine risk assessment and mitigation strategies that increase the likelihood of success for moving the right candidate into the clinic.
Collapse
Affiliation(s)
- Carl Mieczkowski
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Xuejin Zhang
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Dana Lee
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Khanh Nguyen
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Wei Lv
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Yanling Wang
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Yue Zhang
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Jackie Way
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Jean-Michel Gries
- President, Discovery Research, Hengenix Biotech, Inc, Milpitas, CA, USA
| |
Collapse
|
4
|
Beck A, Nowak C, Meshulam D, Reynolds K, Chen D, Pacardo DB, Nicholls SB, Carven GJ, Gu Z, Fang J, Wang D, Katiyar A, Xiang T, Liu H. Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants. Antibodies (Basel) 2022; 11:73. [PMID: 36412839 PMCID: PMC9703962 DOI: 10.3390/antib11040073] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/27/2022] [Accepted: 11/11/2022] [Indexed: 09/28/2023] Open
Abstract
Since the first approval of the anti-CD3 recombinant monoclonal antibody (mAb), muromonab-CD3, a mouse antibody for the prevention of transplant rejection, by the US Food and Drug Administration (FDA) in 1986, mAb therapeutics have become increasingly important to medical care. A wealth of information about mAbs regarding their structure, stability, post-translation modifications, and the relationship between modification and function has been reported. Yet, substantial resources are still required throughout development and commercialization to have appropriate control strategies to maintain consistent product quality, safety, and efficacy. A typical feature of mAbs is charge heterogeneity, which stems from a variety of modifications, including modifications that are common to many mAbs or unique to a specific molecule or process. Charge heterogeneity is highly sensitive to process changes and thus a good indicator of a robust process. It is a high-risk quality attribute that could potentially fail the specification and comparability required for batch disposition. Failure to meet product specifications or comparability can substantially affect clinical development timelines. To mitigate these risks, the general rule is to maintain a comparable charge profile when process changes are inevitably introduced during development and even after commercialization. Otherwise, new peaks or varied levels of acidic and basic species must be justified based on scientific knowledge and clinical experience for a specific molecule. Here, we summarize the current understanding of mAb charge variants and outline risk-based control strategies to support process development and ultimately commercialization.
Collapse
Affiliation(s)
- Alain Beck
- Centre d’Immunologie Pierre-Fabre (CIPF), 5 Avenue Napoléon III, 74160 Saint-Julien-en-Genevois, France
| | - Christine Nowak
- Protein Characterization, Alexion AstraZeneca Rare Disease, 100 College St., New Haven, CT 06510, USA
| | - Deborah Meshulam
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Kristina Reynolds
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - David Chen
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Dennis B. Pacardo
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Samantha B. Nicholls
- Protein Sciences, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Gregory J. Carven
- Research, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Zhenyu Gu
- Jasper Therapeutics, Inc., 2200 Bridge Pkwy Suite 102, Redwood City, CA 94065, USA
| | - Jing Fang
- Biological Drug Discovery, Biogen, 225 Binney St., Cambridge, MA 02142, USA
| | - Dongdong Wang
- Global Biologics, Takeda Pharmaceuticals, 300 Shire Way, Lexington, MA 02421, USA
| | - Amit Katiyar
- CMC Technical Operations, Magenta Therapeutics, 100 Technology Square, Cambridge, MA 02139, USA
| | - Tao Xiang
- Downstream Process and Analytical Development, Boston Institute of Biotechnology, 225 Turnpike Rd., Southborough, MA 01772, USA
| | - Hongcheng Liu
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| |
Collapse
|
5
|
Baginski TK, Veeravalli K, McKenna R, Williams C, Wong K, Tsai C, Hewitt D, Mani K, Laird MW. Enzymatic basis of the Fc-selective intra-chain disulfide reduction and free thiol content variability in an antibody produced in Escherichia coli. Microb Cell Fact 2022; 21:167. [PMID: 35986313 PMCID: PMC9392285 DOI: 10.1186/s12934-022-01892-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Accepted: 08/11/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Escherichia coli (E. coli) is a promising host for production of recombinant proteins (including antibodies and antibody fragments) that don’t require complex post-translational modifications such as glycosylation. During manufacturing-scale production of a one-armed antibody in E. coli (periplasmic production), variability in the degree of reduction of the antibody’s disulfide bonds was observed. This resulted in variability in the free thiol content, a potential critical product quality attribute. This work was initiated to understand and prevent the variability in the total free thiol content during manufacturing.
Results
In this study, we found that the reduction in antibody’s disulfide bonds was observed to occur during homogenization and the ensuing homogenate hold step where in the antibody is exposed to redox enzymes and small molecule reductants present in homogenate. Variability in the downstream processing time between the start of homogenization and end of the homogenate hold step resulted in variability in the degree of antibody disulfide bond reduction and free thiol content. The disulfide bond reduction in the homogenate is catalyzed by the enzyme disulfide bond isomerase C (DsbC) and is highly site-specific and occurred predominantly in the intra-chain disulfide bonds present in the Fc CH2 region. Our results also imply that lack of glycans in E. coli produced antibodies may facilitate DsbC accessibility to the disulfide bond in the Fc CH2 region, resulting in its reduction.
Conclusions
During E. coli antibody manufacturing processes, downstream processing steps such as homogenization and subsequent processing of the homogenate can impact degree of disulfide bond reduction in the antibody and consequently product quality attributes such as total free thiol content. Duration of the homogenate hold step should be minimized as much as possible to prevent disulfide bond reduction and free thiol formation. Other approaches such as reducing homogenate temperature, adding flocculants prior to homogenization, using enzyme inhibitors, or modulating redox environments in the homogenate should be considered to prevent antibody disulfide bond reduction during homogenization and homogenate processing steps in E. coli antibody manufacturing processes.
Collapse
|
6
|
Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China. BIOMED RESEARCH INTERNATIONAL 2022; 2022:7868391. [PMID: 35535043 PMCID: PMC9078787 DOI: 10.1155/2022/7868391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 03/28/2022] [Indexed: 11/17/2022]
Abstract
The proposed biosimilar candidate needs to demonstrate biosimilarity with reference products, and the quality target product profile and biosimilarity assessment criteria are prerequisite, which should be based on extensive characterization of the reference products. In this study, 13 lots of China-sourced pertuzumab (trademark: Perjeta®), with an expiration date from 2020 to 2021, were comprehensively characterized. Despite the consistency of purity, drifts in N-glycan profile were observed, which resulted in the variation of antibody-dependent cellular cytotoxicity (ADCC) activity. In detail, four parametric curves of ADCC activity of the reference product were unparalleled, and the maximum response value was highly related to the content of %afucose than half-maximal effective concentration (EC50). As ADCC is a potential critical quality attribute of Perjeta®, the glycosylation of Perjeta® and its biosimilars should be tightly monitored and controlled.
Collapse
|
7
|
Guo C, Chen F, Xiao Q, Catterall HB, Robinson JH, Wang Z, Mock M, Hubert R. Expression liabilities in a four-chain bispecific molecule. Biotechnol Bioeng 2021; 118:3744-3759. [PMID: 34110008 DOI: 10.1002/bit.27850] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 05/07/2021] [Accepted: 06/01/2021] [Indexed: 12/18/2022]
Abstract
Multispecific antibodies, often composed of three to five polypeptide chains, have become increasingly relevant in the development of biotherapeutics. These molecules have mechanisms of action that include redirecting T cells to tumors and blocking multiple pathogenic mediators simultaneously. One of the major challenges for asymmetric multispecific antibodies is generating a high proportion of the correctly paired antibody during production. To understand the causes and effects of chain mispairing impurities in a difficult to express multispecific hetero-IgG, we investigated consequences of individual and pairwise chain expression in mammalian transient expression hosts. We found that one of the two light chains (LC) was not secretion competent when transfected individually or cotransfected with the noncognate heavy chain (HC). Overexpression of this secretion impaired LC reduced cell growth while inducing endoplasmic reticulum stress and CCAAT/enhancer-binding protein homologous protein (CHOP) expression. The majority of this LC was observed as monomer with incomplete intrachain disulfide bonds when expressed individually. Russell bodies (RB) were induced when this LC was co-expressed with the cognate HC. Moreover, one HC paired promiscuously with noncognate LC. These results identify the causes for the low product quality observed from stable cell lines expressing this heteroIgG and suggest mitigation strategies to improve overall process productivity of the correctly paired multispecific antibody. The approach described here provides a general strategy for identifying the molecular and cellular liabilities associated with difficult to express multispecific antibodies.
Collapse
Affiliation(s)
- Cai Guo
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., Thousand Oaks, California, USA
| | - Fuyi Chen
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., Thousand Oaks, California, USA
| | - Qiang Xiao
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., Thousand Oaks, California, USA
| | - Hannah B Catterall
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., Thousand Oaks, California, USA
| | - John H Robinson
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., Thousand Oaks, California, USA
| | - Zhulun Wang
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., San Francisco, California, USA
| | - Marissa Mock
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., Thousand Oaks, California, USA
| | - René Hubert
- Department of Therapeutic Discovery, Amgen Research, Amgen Inc., Thousand Oaks, California, USA
| |
Collapse
|
8
|
Zhang Y, Qi P. Determination of free sulfhydryl contents for proteins including monoclonal antibodies by use of SoloVPE. J Pharm Biomed Anal 2021; 201:114092. [PMID: 33984827 DOI: 10.1016/j.jpba.2021.114092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Revised: 04/07/2021] [Accepted: 04/19/2021] [Indexed: 01/01/2023]
Abstract
Free sulfhydryls are important properties of protein products including monoclonal antibodies (mAbs). Here, a new technology, variable pathlength extension (SoloVPE), is employed to quantify the amount of free sulfhydryl in monoclonal antibodies (mAbs) using the well-known Ellman reagent. Briefly, the unbound thiols (free sulfhydryls) of proteins including mAbs react with Ellman reagent to produce a 2-nitro-5-thiobenzoate (TNB2-) which is detected at visible wavelength of 412 nm and quantified. The method does not require dilution of antibody samples, is simple, reproducible and takes less than one hour to complete. Values obtained by the new method are compared to literature values from traditional UV or fluorescence methods with agreements. Qualification and trending data over two years of method utilization in our labs support that assay variability is minimal with an intermediate precision of relative standard deviation (RSD) ≤ 10 % and a limit of quantification (LOQ) of 0.1 mol/mol, which is sufficient to measure free sulfhydryl content in proteins including mAbs.
Collapse
Affiliation(s)
- Yuling Zhang
- Analytical and Formulation Department, Lundbeck Seattle BioPharmaceuticals, Inc, 11804 North Creek Parkway South, Bothell, Washington, 98011, United States.
| | - Pei Qi
- Analytical and Formulation Department, Lundbeck Seattle BioPharmaceuticals, Inc, 11804 North Creek Parkway South, Bothell, Washington, 98011, United States
| |
Collapse
|
9
|
Li X, Xiao L, Kochert B, Donnelly DP, Gao X, Richardson D. Extended characterization of unpaired cysteines in an IgG1 monoclonal antibody by LC-MS analysis. Anal Biochem 2021; 622:114172. [PMID: 33766578 DOI: 10.1016/j.ab.2021.114172] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 03/07/2021] [Accepted: 03/15/2021] [Indexed: 01/23/2023]
Abstract
The development of comprehensive methods to characterize unpaired cysteines in monoclonal antibodies (mAbs) is very important for understanding structural heterogeneity, impurity, and stability. In this paper, unpaired cysteines observed in a therapeutic antibody (mAb1) were thoroughly studied by Liquid Chromatography-Mass Spectrometry (LC-MS) methods at the intact mAb, domain, and peptide levels. Three cysteine variants were observed at the intact mAb level with each variant containing two unpaired cysteines. Variants containing four or six unpaired cysteines were not observed. Domain analysis indicated that two Fab variants, each containing two unpaired cysteines, were present while the third variant contained two unpaired cysteines on the Fc region. Peptide mapping analysis localized the six unpaired cysteines to Cys22/Cys96, Cys146/Cys202, and Cys369/Cys427 in the heavy chain. No significant changes were observed for these unpaired cysteines in mAb1 under high pH and heat-stressed conditions. Structural analysis and molecular modeling revealed that these unpaired cysteines were buried inside the three-dimensional structure. The integrated LC-MS methods together with stress studies and structural analysis may potentially be applied to the analysis of unpaired cysteines in other mAbs.
Collapse
Affiliation(s)
- Xiaojuan Li
- Analytical Research & Development Mass Spectrometry, MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.
| | - Li Xiao
- Computational and Structural Chemistry, MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Brent Kochert
- Analytical Research & Development Mass Spectrometry, MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Daniel P Donnelly
- Analytical Research & Development Mass Spectrometry, MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Xinliu Gao
- Analytical Research & Development Mass Spectrometry, MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Douglas Richardson
- Analytical Research & Development Mass Spectrometry, MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| |
Collapse
|
10
|
Kim MT, Lechmann M, Rajan S, Shivva V, Lee A, Chen Y, Weis DD. In Vivo Reoxidation Kinetics of Free Thiols in Multiple Domains of IgG1 Antibodies in Rats. J Pharm Sci 2021; 110:1989-1996. [PMID: 33617870 DOI: 10.1016/j.xphs.2021.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 02/08/2021] [Accepted: 02/09/2021] [Indexed: 11/28/2022]
Abstract
While free thiols in monoclonal antibodies (mAbs) have been extensively characterized by in vitro studies to probe its effect on antibody function and stability, their in vivo biotransformation has not been comprehensively studied. In this study, a panel of five recombinant IgG1 mAbs with elevated free thiols in the VH, VL, and CH2 domains were intravenously administered into Wistar rats. In vivo biotransformation of thirty-five free thiol sites in total (7 disulfide pairs in VL, CL, VH, CH1, HH, CH2, CH3 domains across the 5 mAbs) were monitored using a denaturing differential isotopic tagging procedure on immunopurified timepoints followed by LC-MS of tryptic digests. The free thiol levels in two VH domain and one CH2 domain disulfide sites decreased in vivo following first order kinetics. Free thiol levels of the remaining 32 sites were remarkably stable in vivo. Further analytical characterization highlighted a positive association between a free thiol's solvent accessibility and a free thiol's reoxidation propensity. The data and discussion presented here shed valuable insights into the in vivo fate of free thiols in several recombinant IgG1s and its implications for free thiols as a product quality attribute in therapeutic mAb products.
Collapse
Affiliation(s)
- Michael T Kim
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California, USA; Department of Chemistry, University of Kansas, Lawrence, Kansas, USA.
| | - Martin Lechmann
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Penzberg, Germany
| | - Sharmila Rajan
- Department of Preclinical and Translation Pharmacokinetics, Genentech, South San Francisco, California, USA
| | - Vittal Shivva
- Department of Preclinical and Translation Pharmacokinetics, Genentech, South San Francisco, California, USA
| | - Aron Lee
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California, USA
| | - Yan Chen
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California, USA
| | - David D Weis
- Department of Chemistry, University of Kansas, Lawrence, Kansas, USA
| |
Collapse
|
11
|
Mieczkowski C, Bahmanjah S, Yu Y, Baker J, Raghunathan G, Tomazela D, Hsieh M, McCoy M, Strickland C, Fayadat-Dilman L. Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies. Antibodies (Basel) 2020; 9:antib9040066. [PMID: 33266498 PMCID: PMC7709113 DOI: 10.3390/antib9040066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2020] [Revised: 10/20/2020] [Accepted: 11/09/2020] [Indexed: 11/23/2022] Open
Abstract
We report the novel crystal structure and characterization of symmetrical, homodimeric humanized heavy-chain-only antibodies or dimers (HC2s). HC2s were found to be significantly coexpressed and secreted along with mAbs from transient CHO HC/LC cotransfection, resulting in an unacceptable mAb developability attribute. Expression of full-length HC2s in the absence of LC followed by purification resulted in HC2s with high purity and thermal stability similar to conventional mAbs. The VH and CH1 portion of the heavy chain (or Fd) was also efficiently expressed and yielded a stable, covalent, and reducible dimer (Fd2). Mutagenesis of all heavy chain cysteines involved in disulfide bond formation revealed that Fd2 intermolecular disulfide formation was similar to Fabs and elucidated requirements for Fd2 folding and expression. For one HC2, we solved the crystal structure of the Fd2 domain to 2.9 Å, revealing a highly symmetrical homodimer that is structurally similar to Fabs and is mediated by conserved (CH1) and variable (VH) contacts with all CDRs positioned outward for target binding. Interfacial dimer contacts revealed by the crystal structure were mutated for two HC2s and were found to dramatically affect HC2 formation while maintaining mAb bioactivity, offering a potential means to modulate novel HC2 formation through engineering. These findings indicate that human heavy-chain dimers can be secreted efficiently in the absence of light chains, may show good physicochemical properties and stability, are structurally similar to Fabs, offer insights into their mechanism of formation, and may be amenable as a novel therapeutic modality.
Collapse
Affiliation(s)
- Carl Mieczkowski
- Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA; (Y.Y.); (J.B.); (G.R.); (D.T.); (M.H.); (L.F.-D.)
- Correspondence: ; Tel.: +1-650-496-6501
| | - Soheila Bahmanjah
- Department of Chemistry, Modeling and Informatics, Merck & Co., Inc., Kenilworth, NJ 07033, USA; (S.B.); (C.S.)
| | - Yao Yu
- Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA; (Y.Y.); (J.B.); (G.R.); (D.T.); (M.H.); (L.F.-D.)
| | - Jeanne Baker
- Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA; (Y.Y.); (J.B.); (G.R.); (D.T.); (M.H.); (L.F.-D.)
| | - Gopalan Raghunathan
- Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA; (Y.Y.); (J.B.); (G.R.); (D.T.); (M.H.); (L.F.-D.)
| | - Daniela Tomazela
- Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA; (Y.Y.); (J.B.); (G.R.); (D.T.); (M.H.); (L.F.-D.)
| | - Mark Hsieh
- Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA; (Y.Y.); (J.B.); (G.R.); (D.T.); (M.H.); (L.F.-D.)
| | - Mark McCoy
- Department of Pharmacology, Mass Spectrometry & Biophysics, Merck & Co., Inc., Kenilworth, NJ 07033, USA;
| | - Corey Strickland
- Department of Chemistry, Modeling and Informatics, Merck & Co., Inc., Kenilworth, NJ 07033, USA; (S.B.); (C.S.)
| | - Laurence Fayadat-Dilman
- Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA; (Y.Y.); (J.B.); (G.R.); (D.T.); (M.H.); (L.F.-D.)
| |
Collapse
|
12
|
Swierczynski MJ, Ball ZT. One-Step Protein-Polymer Conjugates from Boronic-Acid-Functionalized Polymers. Bioconjug Chem 2020; 31:2494-2498. [PMID: 33078937 DOI: 10.1021/acs.bioconjchem.0c00516] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Polymer-protein conjugates are hybrid materials with interesting and useful properties. Methods to prepare diverse diblock materials of this sort often struggle to deal with the complexity and size of reagents, and so polymer-protein conjugation represents a stringent testing ground for nontraditional bioconjugation methods, such as metal-catalyzed arylation. This work demonstrates a simple Ni2+-promoted arylation of cysteine residues with end-functionalized polymer-boronic acid reagents, and explores some molecular and physical properties possible in these hybrid structures.
Collapse
Affiliation(s)
- Michael J Swierczynski
- Department of Chemistry, Rice University, 6100 Main Street, Bioscience Research Collaborative, Houston, Texas 77005, United States
| | - Zachary T Ball
- Department of Chemistry, Rice University, 6100 Main Street, Bioscience Research Collaborative, Houston, Texas 77005, United States
| |
Collapse
|
13
|
Wei B, Jia W, Yang Y, Jazayri M, Fulchiron D, Jeong J, Cai Q, Li C, Briggs J, Ninonuevo M, Liu H, Liu Z, Zhang YT. Development of a rapid reversed-phase liquid chromatographic method for total free thiol quantitation in protein therapeutics. J Pharm Biomed Anal 2020; 189:113434. [DOI: 10.1016/j.jpba.2020.113434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 06/10/2020] [Accepted: 06/16/2020] [Indexed: 10/24/2022]
|
14
|
Wang D, Nowak C, Mason B, Katiyar A, Liu H. Analytical artifacts in characterization of recombinant monoclonal antibody therapeutics. J Pharm Biomed Anal 2020; 183:113131. [DOI: 10.1016/j.jpba.2020.113131] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 01/22/2020] [Accepted: 01/24/2020] [Indexed: 01/12/2023]
|
15
|
Liu YD, Chen Y, Tsui G, Wei B, Yang F, Yu C, Cornell C. Predictive In Vitro Vitreous and Serum Models and Methods to Assess Thiol-Related Quality Attributes in Protein Therapeutics. Anal Chem 2020; 92:6869-6876. [DOI: 10.1021/acs.analchem.9b05176] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
16
|
Seo Y, Lee Y, Kim M, Park H, Kwon MH. Assembly and Folding Properties of Cytosolic IgG Intrabodies. Sci Rep 2020; 10:2140. [PMID: 32034177 PMCID: PMC7005851 DOI: 10.1038/s41598-020-58798-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 01/21/2020] [Indexed: 11/15/2022] Open
Abstract
Intrabodies, antibodies expressed within cells, offer an interesting way to target intracellular molecules, making them potentially useful for biotechnology and medicine. However, it remains controversial whether full-size IgG intrabodies expressed in the reducing environment of the cytosol of mammalian cells are workable and structurally sound. Herein, we settle this issue with a systematic investigation of the structure and functionality of four chimeric IgG1s with distinct variable (V) domains but identical constant (C) domains. Full-size IgGs expressed in the cytosol of HEK293 cells were either assembly-competent or -incompetent, depending on the intrinsic properties of the V regions. Structural integrity of the C region is required for H:L association and the formation of a functional antigen-binding site. Partial intrachain disulfide bond formation occurs in both H and L chains of cytosolic IgG intrabodies, whereas interchain disulfide bond formation was absent and dispensable for functional assembly. IgG1s expressed in the cytosol and via the ER were shown to assemble differently. Our findings provide insight into the features and possible utilization of full-size IgGs as cytosolic antibodies in biotechnological and medical applications.
Collapse
Affiliation(s)
- Youngsil Seo
- Department of Biomedical Sciences, Graduate School, Ajou University, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea.,Department of Microbiology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea
| | - Yeonjin Lee
- Department of Biomedical Sciences, Graduate School, Ajou University, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea.,Department of Microbiology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea
| | - Minjae Kim
- Department of Biomedical Sciences, Graduate School, Ajou University, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea.,Department of Microbiology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea
| | - Hyunjoon Park
- Department of Biomedical Sciences, Graduate School, Ajou University, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea.,Department of Microbiology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea
| | - Myung-Hee Kwon
- Department of Biomedical Sciences, Graduate School, Ajou University, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea. .,Department of Microbiology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon, 16499, Gyeonggi-do, South Korea.
| |
Collapse
|
17
|
Yu C, Zhang F, Xu G, Wu G, Wang W, Liu C, Fu Z, Li M, Guo S, Yu X, Wang L. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab. Anal Chem 2020; 92:3161-3170. [DOI: 10.1021/acs.analchem.9b04871] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Chuanfei Yu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Feng Zhang
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Gangling Xu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Gang Wu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Wenbo Wang
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Chunyu Liu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Zhihao Fu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Meng Li
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Sha Guo
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Xiaojuan Yu
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| | - Lan Wang
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 29, Huatuo Road, Daxing District, Beijing 102629, China
| |
Collapse
|
18
|
Wei B, Han G, Tang J, Sandoval W, Zhang YT. Native Hydrophobic Interaction Chromatography Hyphenated to Mass Spectrometry for Characterization of Monoclonal Antibody Minor Variants. Anal Chem 2019; 91:15360-15364. [DOI: 10.1021/acs.analchem.9b04467] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Bingchuan Wei
- Department of Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Guanghui Han
- Department of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jia Tang
- Department of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Wendy Sandoval
- Department of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Yonghua Taylor Zhang
- Department of Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
19
|
Modifications of recombinant monoclonal antibodies in vivo. Biologicals 2019; 59:1-5. [DOI: 10.1016/j.biologicals.2019.03.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Revised: 12/07/2018] [Accepted: 03/15/2019] [Indexed: 12/16/2022] Open
|
20
|
Application of a label-free and domain-specific free thiol method in monoclonal antibody characterization. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1114-1115:93-99. [DOI: 10.1016/j.jchromb.2019.03.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 03/07/2019] [Accepted: 03/25/2019] [Indexed: 12/17/2022]
|
21
|
Robotham AC, Kelly JF. Detection and quantification of free sulfhydryls in monoclonal antibodies using maleimide labeling and mass spectrometry. MAbs 2019; 11:757-766. [PMID: 30894096 PMCID: PMC6601545 DOI: 10.1080/19420862.2019.1595307] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Revised: 02/27/2019] [Accepted: 03/08/2019] [Indexed: 11/28/2022] Open
Abstract
The detection of free sulfhydryls in proteins can reveal incomplete disulfide bond formation, indicate cysteine residues available for conjugation, and offer insights into protein stability and structure. Traditional spectroscopic methods of free sulfhydryl detection, such as Ellman's reagent, generally require a relatively large amount of sample, preventing their use for the analysis of biotherapeutics early in the development cycle. These spectroscopic methods also cannot accurately determine the location of the free sulfhydryl, further limiting their utility. Mass spectrometry was used to detect free sulfhydryl residues in intact proteins after labeling with Maleimide-PEG2-Biotin. As little as 2% cysteine residues with free sulfhydryls (0.02 mol SH per mol protein) could be detected by this method. Following reduction, the free sulfhydryl abundance on antibody heavy and light chains could be measured. To determine free sulfhydryl location at peptide-level resolution, free sulfhydryls and cysteines involved in disulfide bonds were differentially labeled with N-ethylmaleimide and d5-N-ethylmaleimide, respectively. Following enzymatic digestion and nanoLC-MS, the abundance of free sulfhydryls at individual cysteine residues was quantified down to 2%. The method was optimized to avoid non-specific labeling, disulfide bond scrambling, and maleimide exchange and hydrolysis. This new workflow for free sulfhydryl analysis was used to measure the abundance and location of free sulfhydryls in 3 commercially available monoclonal antibody standards (NIST Monoclonal Antibody Reference Material (NIST), SILu™Lite SigmaMAb Universal Antibody Standard (Sigma-Aldrich) and Intact mAb Mass Check Standard (Waters)) and 1 small protein standard (β-Lactoglobulin A).
Collapse
Affiliation(s)
- Anna C. Robotham
- Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa, Ontario, Canada
| | - John F. Kelly
- Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa, Ontario, Canada
| |
Collapse
|
22
|
Beck A, Liu H. Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies. Antibodies (Basel) 2019; 8:antib8010018. [PMID: 31544824 PMCID: PMC6640695 DOI: 10.3390/antib8010018] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2018] [Revised: 01/19/2019] [Accepted: 02/13/2019] [Indexed: 12/22/2022] Open
Abstract
Recombinant monoclonal antibodies (mAbs) intended for therapeutic usage are required to be thoroughly characterized, which has promoted an extensive effort towards the understanding of the structures and heterogeneity of this major class of molecules. Batch consistency and comparability are highly relevant to the successful pharmaceutical development of mAbs and related products. Small structural modifications that contribute to molecule variants (or proteoforms) differing in size, charge or hydrophobicity have been identified. These modifications may impact (or not) the stability, pharmacokinetics, and efficacy of mAbs. The presence of the same type of modifications as found in endogenous immunoglobulin G (IgG) can substantially lower the safety risks of mAbs. The knowledge of modifications is also critical to the ranking of critical quality attributes (CQAs) of the drug and define the Quality Target Product Profile (QTPP). This review provides a summary of the current understanding of post-translational and physico-chemical modifications identified in recombinant mAbs and endogenous IgGs at physiological conditions.
Collapse
Affiliation(s)
- Alain Beck
- Biologics CMC and developability, IRPF, Center d'immunologie Pierre Fabre, St Julien-en-Genevois CEDEX, 74160 Saint-Julien en Genevois, France.
| | - Hongcheng Liu
- Anokion, 50 Hampshire Street, Suite 402, Cambridge, MA 02139, USA.
| |
Collapse
|
23
|
Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, Nowak C, Xiang T, Dong DD, Sun J, Beck A, Liu H. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs 2018; 11:239-264. [PMID: 30543482 DOI: 10.1080/19420862.2018.1553476] [Citation(s) in RCA: 155] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Increasing attention has been paid to developability assessment with the understanding that thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid delays during late-stage development. The concept of developability is based on the knowledge gained from the successful development of approximately 80 marketed antibody and Fc-fusion protein drug products and from the lessons learned from many failed development programs over the last three decades. Here, we reviewed antibody quality attributes that are critical to development and traditional and state-of-the-art analytical methods to monitor those attributes. Based on our collective experiences, a practical workflow is proposed as a best practice for developability assessment including in silico evaluation, extended characterization and forced degradation using appropriate analytical methods that allow characterization with limited material consumption and fast turnaround time.
Collapse
Affiliation(s)
- Yingda Xu
- a Protein Analytics , Adimab , Lebanon , NH , USA
| | - Dongdong Wang
- b Analytical Department , Bioanalytix, Inc ., Cambridge , MA , USA
| | - Bruce Mason
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| | - Tony Rossomando
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| | - Ning Li
- d Analytical Chemistry , Regeneron Pharmaceuticals, Inc ., Tarrytown , NY , USA
| | - Dingjiang Liu
- e Formulation Development , Regeneron Pharmaceuticals, Inc ., Tarrytown , NY , USA
| | - Jason K Cheung
- f Pharmaceutical Sciences , MRL, Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Wei Xu
- g Analytical Method Development , MRL, Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Smita Raghava
- h Sterile Formulation Sciences , MRL, Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Amit Katiyar
- i Analytical Development , Bristol-Myers Squibb , Pennington , NJ , USA
| | - Christine Nowak
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| | - Tao Xiang
- j Manufacturing Sciences , Abbvie Bioresearch Center , Worcester , MA , USA
| | - Diane D Dong
- j Manufacturing Sciences , Abbvie Bioresearch Center , Worcester , MA , USA
| | - Joanne Sun
- k Product development , Innovent Biologics , Suzhou Industrial Park , China
| | - Alain Beck
- l Analytical chemistry , NBEs, Center d'immunologie Pierre Fabre , St Julien-en-Genevois Cedex , France
| | - Hongcheng Liu
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| |
Collapse
|
24
|
Baker JJ, McDaniel D, Cain D, Lee Tao P, Li C, Huang Y, Liu H, Zhu-Shimoni J, Niñonuevo M. Rapid Identification of Disulfide Bonds and Cysteine-Related Variants in an IgG1 Knob-into-Hole Bispecific Antibody Enhanced by Machine Learning. Anal Chem 2018; 91:965-976. [DOI: 10.1021/acs.analchem.8b04071] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Jordan J. Baker
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Dana McDaniel
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - David Cain
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Paula Lee Tao
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Charlene Li
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Yuting Huang
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Hongbin Liu
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Judith Zhu-Shimoni
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Milady Niñonuevo
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
25
|
Spahr CS, Daris ME, Graham KC, Soriano BD, Stevens JL, Shi SDH. Discovery, characterization, and remediation of a C-terminal Fc-extension in proteins expressed in CHO cells. MAbs 2018; 10:1291-1300. [PMID: 30148415 DOI: 10.1080/19420862.2018.1511197] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
Protein-based biotherapeutics are produced in engineered cells through complex processes and may contain a wide variety of variants and post-translational modifications that must be monitored or controlled to ensure product quality. Recently, a low level (~1-5%) impurity was observed in a number of proteins derived from stably transfected Chinese hamster ovary (CHO) cells using mass spectrometry. These molecules include antibodies and Fc fusion proteins where Fc is on the C-terminus of the construct. By liquid chromatography-mass spectrometry (LC-MS), the impurity was found to be ~1177 Da larger than the expected mass. After tryptic digestion and analysis by LC-MS/MS, the impurity was localized to the C-terminus of Fc in the form of an Fc sequence extension. Targeted higher-energy collision dissociation was performed using various normalized collision energies (NCE) on two charge states of the extended peptide, resulting in nearly complete fragment ion coverage. The amino acid sequence, SLSLSPEAEAASASELFQ, obtained by the de novo sequencing effort matches a portion of the vector sequence used in the transfection of the CHO cells, specifically in the promoter region of the selection cassette downstream of the protein coding sequence. The modification was the result of an unexpected splicing event, caused by the resemblance of the commonly used GGU codon of the C-terminal glycine to a consensus splicing donor. Three alternative codons for glycine were tested to alleviate the modification, and all were found to completely eliminate the undesirable C-terminal extension, thus improving product quality.
Collapse
Affiliation(s)
- Christopher S Spahr
- a Discovery Attribute Sciences, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Mark E Daris
- b Biologics Optimization, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Kevin C Graham
- b Biologics Optimization, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Brian D Soriano
- a Discovery Attribute Sciences, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Jennitte L Stevens
- b Biologics Optimization, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| | - Stone D-H Shi
- a Discovery Attribute Sciences, Therapeutic Discovery , Amgen Discovery Research , Thousand Oaks , CA , USA
| |
Collapse
|
26
|
Welch L, Dong X, Hewitt D, Irwin M, McCarty L, Tsai C, Baginski T. Facile quantitation of free thiols in a recombinant monoclonal antibody by reversed-phase high performance liquid chromatography with hydrophobicity-tailored thiol derivatization. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1092:158-167. [DOI: 10.1016/j.jchromb.2018.05.039] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2017] [Revised: 04/26/2018] [Accepted: 05/27/2018] [Indexed: 12/16/2022]
|
27
|
Chen W, Mack A, Sachok B, Jiang K, Wang X. Performance of Optimized Wide Pore Superficially Porous Particles for Separation of Proteins and Immunoglobulin G Antibodies. J Chromatogr Sci 2018. [PMID: 29522182 DOI: 10.1093/chromsci/bmy016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
In this study, we studied the chromatographic performance of this newly developed wide pore superficially porous particles (SPPs) with 3.5 μm particle size and 450 Å pore size, for the separation of proteins and Immunoglobulin G antibodies. We studied the selectivity of different phases (C4, SB-C18 and Diphenyl), the effect of temperature, column carryover and column chemical lifetime. We also compared our SPPs with other wide pore SPPs in similar particle sizes and sub 2 µ wide pore totally porous particles by van Deemter studies and gradient separations of proteins and immunoglobulin G antibodies. The results showed that the SPPs containing larger pore size gave better chromatographic performance.
Collapse
Affiliation(s)
- Wu Chen
- Agilent Technologies, Inc., 2850 Centerville Road, Wilmington, DE 19808, USA
| | - Anne Mack
- Agilent Technologies, Inc., 2850 Centerville Road, Wilmington, DE 19808, USA
| | - Bo Sachok
- Agilent Technologies, Inc., 2850 Centerville Road, Wilmington, DE 19808, USA
| | - Kunqiang Jiang
- Agilent Technologies, Inc., 2850 Centerville Road, Wilmington, DE 19808, USA
| | - Xiaoli Wang
- Agilent Technologies, Inc., 2850 Centerville Road, Wilmington, DE 19808, USA
| |
Collapse
|
28
|
Mazzoccanti G, Pierri G, Ciogli A, Ismail OH, Giorgi F, De Santis R, Villani C, Gasparrini F. Stepwise “bridge-to-bridge” reduction of monoclonal antibodies and light chain detection: Case studies of tenatumomab and trastuzumab. SEPARATION SCIENCE PLUS 2018. [DOI: 10.1002/sscp.201800002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Giulia Mazzoccanti
- Dipartimento di Chimica e Tecnologie del Farmaco; “Sapienza” Università di Roma; Roma Italy
| | - Giuseppe Pierri
- Dipartimento di Chimica e Tecnologie del Farmaco; “Sapienza” Università di Roma; Roma Italy
| | - Alessia Ciogli
- Dipartimento di Chimica e Tecnologie del Farmaco; “Sapienza” Università di Roma; Roma Italy
| | - Omar H. Ismail
- Dipartimento di Chimica e Tecnologie del Farmaco; “Sapienza” Università di Roma; Roma Italy
| | | | | | - Claudio Villani
- Dipartimento di Chimica e Tecnologie del Farmaco; “Sapienza” Università di Roma; Roma Italy
| | - Francesco Gasparrini
- Dipartimento di Chimica e Tecnologie del Farmaco; “Sapienza” Università di Roma; Roma Italy
| |
Collapse
|
29
|
Ambrogelly A, Gozo S, Katiyar A, Dellatore S, Kune Y, Bhat R, Sun J, Li N, Wang D, Nowak C, Neill A, Ponniah G, King C, Mason B, Beck A, Liu H. Analytical comparability study of recombinant monoclonal antibody therapeutics. MAbs 2018; 10:513-538. [PMID: 29513619 PMCID: PMC5973765 DOI: 10.1080/19420862.2018.1438797] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 01/30/2018] [Accepted: 02/05/2018] [Indexed: 10/17/2022] Open
Abstract
Process changes are inevitable in the life cycle of recombinant monoclonal antibody therapeutics. Products made using pre- and post-change processes are required to be comparable as demonstrated by comparability studies to qualify for continuous development and commercial supply. Establishment of comparability is a systematic process of gathering and evaluating data based on scientific understanding and clinical experience of the relationship between product quality attributes and their impact on safety and efficacy. This review summarizes the current understanding of various modifications of recombinant monoclonal antibodies. It further outlines the critical steps in designing and executing successful comparability studies to support process changes at different stages of a product's lifecycle.
Collapse
Affiliation(s)
- Alexandre Ambrogelly
- Biologics Analytical Operations, Pharmaceutical & Biologics Development, Gilead Sciences, Ocean Ranch Blvd, Oceanside, CA
| | - Stephen Gozo
- Analytical Research & Development-Biologics, Celgene Corporation, Morris Avenue, Summit, NJ
| | - Amit Katiyar
- Analytical Development, Bristol-Myers Squibb, Pennington Rocky Road, Pennington, NJ
| | - Shara Dellatore
- Biologics & Vaccines Bioanalytics, MRL, Merck & Co., Inc., Galloping Hill Road, Kenilworth, NJ USA
| | - Yune Kune
- Fortress Biologicals, Sawyer Road, Suite, Waltham, MA
| | - Ram Bhat
- Millennium Research laboratories, New Boston Street, Woburn, MA
| | - Joanne Sun
- Product Development, Innovent Biologics, Dongping Street, Suzhou Industrial Park, China
| | - Ning Li
- Analytical Chemistry, Regeneron Pharmaceuticals, Inc., Old Saw Mill River Road, Tarrytown, NY
| | - Dongdong Wang
- Analytical Department, BioAnalytix, Inc., Memorial Drive, Cambridge, MA
| | - Christine Nowak
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| | - Alyssa Neill
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| | | | - Cory King
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| | - Bruce Mason
- Pre-formulation, Alexion Pharmaceuticals, College Street, New Haven, CT
| | - Alain Beck
- Analytical Chemistry, NBEs, Center d'Immunologie Pierre Fabre, St Julien-en-Genevois Cedex, France
| | - Hongcheng Liu
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| |
Collapse
|
30
|
Moritz B, Locatelli V, Niess M, Bathke A, Kiessig S, Entler B, Finkler C, Wegele H, Stracke J. Optimization of capillary zone electrophoresis for charge heterogeneity testing of biopharmaceuticals using enhanced method development principles. Electrophoresis 2017; 38:3136-3146. [PMID: 28887890 PMCID: PMC5765393 DOI: 10.1002/elps.201700145] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Revised: 08/05/2017] [Accepted: 08/05/2017] [Indexed: 11/18/2022]
Abstract
CZE is a well-established technique for charge heterogeneity testing of biopharmaceuticals. It is based on the differences between the ratios of net charge and hydrodynamic radius. In an extensive intercompany study, it was recently shown that CZE is very robust and can be easily implemented in labs that did not perform it before. However, individual characteristics of some examined proteins resulted in suboptimal resolution. Therefore, enhanced method development principles were applied here to investigate possibilities for further method optimization. For this purpose, a high number of different method parameters was evaluated with the aim to improve CZE separation. For the relevant parameters, design of experiments (DoE) models were generated and optimized in several ways for different sets of responses like resolution, peak width and number of peaks. In spite of product specific DoE optimization it was found that the resulting combination of optimized parameters did result in significant improvement of separation for 13 out of 16 different antibodies and other molecule formats. These results clearly demonstrate generic applicability of the optimized CZE method. Adaptation to individual molecular properties may sometimes still be required in order to achieve optimal separation but the set screws discussed in this study [mainly pH, identity of the polymer additive (HPC versus HPMC) and the concentrations of additives like acetonitrile, butanolamine and TETA] are expected to significantly reduce the effort for specific optimization.
Collapse
Affiliation(s)
| | | | | | | | | | - Barbara Entler
- IMC Fachhochschule Krems, University of Applied SciencesKremsAustria
| | | | | | | |
Collapse
|
31
|
Wei B, Zhang B, Boyes B, Zhang YT. Reversed-phase chromatography with large pore superficially porous particles for high throughput immunoglobulin G 2 disulfide isoform separation. J Chromatogr A 2017; 1526:104-111. [DOI: 10.1016/j.chroma.2017.10.040] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Revised: 09/21/2017] [Accepted: 10/15/2017] [Indexed: 10/18/2022]
|
32
|
Beyer B, Schuster M, Jungbauer A, Lingg N. Microheterogeneity of Recombinant Antibodies: Analytics and Functional Impact. Biotechnol J 2017; 13. [PMID: 28862393 DOI: 10.1002/biot.201700476] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 08/08/2017] [Indexed: 02/04/2023]
Abstract
Antibodies are typical examples of biopharmaceuticals which are composed of numerous, almost infinite numbers of potential molecular entities called variants or isoforms, which constitute the microheterogeneity of these molecules. These variants are generated during biosynthesis by so-called posttranslational modification, during purification or upon storage. The variants differ in biological properties such as pharmacodynamic properties, for example, Antibody Dependent Cellular Cytotoxicity, complement activation, and pharmacokinetic properties, for example, serum half-life and safety. Recent progress in analytical technologies such as various modes of liquid chromatography and mass spectrometry has helped to elucidate the structure of a lot of these variants and their biological properties. In this review the most important modifications (glycosylation, terminal modifications, amino acid side chain modifications, glycation, disulfide bond variants and aggregation) are reviewed and an attempt is made to give an overview on the biological properties, for which the reports are often contradictory. Even though there is a deep understanding of cellular and molecular mechanism of antibody modification and their consequences, the clinical proof of the effects observed in vitro and in vivo is still not fully rendered. For some modifications such as core-fucosylation of the N-glycan and aggregation the effects are clear and should be monitored, but with others such as C-terminal lysine clipping the reports are contradictory. As a consequence it seems too early to tell if any modification can be safely ignored.
Collapse
Affiliation(s)
- Beate Beyer
- Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria.,Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | | | - Alois Jungbauer
- Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria.,Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - Nico Lingg
- Austrian Centre of Industrial Biotechnology, Vienna, Austria
| |
Collapse
|
33
|
Moritz B, Stracke JO. Assessment of disulfide and hinge modifications in monoclonal antibodies. Electrophoresis 2017; 38:769-785. [PMID: 27982442 PMCID: PMC5413849 DOI: 10.1002/elps.201600425] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 11/25/2016] [Accepted: 12/04/2016] [Indexed: 01/06/2023]
Abstract
During the last years there was a substantial increase in the use of antibodies and related proteins as therapeutics. The emphasis of the pharmaceutical industry is on IgG1, IgG2, and IgG4 antibodies, which are therefore in the focus of this article. In order to ensure appropriate quality control of such biopharmaceuticals, deep understanding of their chemical degradation pathways and the resulting impact on potency, pharmacokinetics, and safety is required. Criticality of modifications may be specific for individual antibodies and has to be assessed for each molecule. However, some modifications of conserved structure elements occur in all or at least most IgGs. In these cases, criticality assessment may be applicable to related molecules or molecule formats. The relatively low dissociation energy of disulfide bonds and the high flexibility of the hinge region frequently lead to modifications and cleavages. Therefore, the hinge region and disulfide bonds require specific consideration during quality assessment of mAbs. In this review, available literature knowledge on underlying chemical reaction pathways of modifications, analytical methods for quantification and criticality are discussed. The hinge region is prone to cleavage and is involved in pathways that lead to thioether bond formation, cysteine racemization, and iso‐Asp (Asp, aspartic acid) formation. Disulfide or sulfhydryl groups were found to be prone to reductive cleavage, trisulfide formation, cysteinylation, glutathionylation, disulfide bridging to further light chains, and disulfide scrambling. With regard to potency, disulfide cleavage, hinge cleavage, disulfide bridging to further light chains, and cysteinylation were found to influence antigen binding and fragment crystallizable (Fc) effector functionalities. Renal clearance of small fragments may be faster, whereas clearance of larger fragments appears to depend on their neonatal Fc receptor (FcRn) functionality, which in turn may be impeded by disulfide bond cleavage. Certain modifications such as disulfide induced aggregation and heterodimers from different antibodies are generally regarded critical with respect to safety. However, the detection of some modifications in endogenous antibodies isolated from human blood and the possibility of in vivo repair mechanisms may reduce some safety concerns.
Collapse
|
34
|
Domain-specific free thiol variant characterization of an IgG1 by reversed-phase high-performance liquid chromatography mass spectrometry. Anal Biochem 2017; 519:8-14. [DOI: 10.1016/j.ab.2016.12.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 12/06/2016] [Indexed: 11/17/2022]
|
35
|
Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals 2016; 44:291-305. [PMID: 27461239 DOI: 10.1016/j.biologicals.2016.06.005] [Citation(s) in RCA: 156] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Accepted: 06/10/2016] [Indexed: 01/06/2023] Open
Abstract
Quality by design (QbD) is a global regulatory initiative with the goal of enhancing pharmaceutical development through the proactive design of pharmaceutical manufacturing process and controls to consistently deliver the intended performance of the product. The principles of pharmaceutical development relevant to QbD are described in the ICH guidance documents (ICHQ8-11). An integrated set of risk assessments and their related elements developed at Roche/Genentech were designed to provide an overview of product and process knowledge for the production of a recombinant monoclonal antibody. This chapter describes the identification of critical quality attributes (CQAs) as an important first step for QbD development of biopharmaceuticals. A systematic scientific based risk ranking and filtering approach allows a thorough understanding of quality attributes and an assignment of criticality for their impact on drug safety and efficacy. To illustrate the application of the approach and tools, a few examples from monoclonal antibodies are shown. The identification of CQAs is a continuous process and will further drive the structure and function characterization of therapeutic proteins.
Collapse
Affiliation(s)
- Nadja Alt
- Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
| | - Taylor Y Zhang
- Pharma Technical Development, Genentech, South San Francisco, CA 94080, USA
| | - Paul Motchnik
- Biologics Quality Control, Genentech, South San Francisco, CA 94080, USA
| | - Ron Taticek
- Pharma Technical Development, Genentech, South San Francisco, CA 94080, USA
| | - Valerie Quarmby
- Research and Early Development, Genentech, South San Francisco, CA 94080 USA
| | - Tilman Schlothauer
- Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany
| | - Hermann Beck
- Pharma Technical Development Biotech Europe, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland
| | - Thomas Emrich
- Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany
| | - Reed J Harris
- Pharma Technical Development, Genentech, South San Francisco, CA 94080, USA
| |
Collapse
|
36
|
Cheng Y, Chen Y, Yu C. Fast and Efficient non-reduced Lys-C digest using pressure cycling technology for antibody disulfide mapping by LC-MS. J Pharm Biomed Anal 2016; 129:203-209. [PMID: 27429370 DOI: 10.1016/j.jpba.2016.07.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 07/01/2016] [Accepted: 07/02/2016] [Indexed: 10/21/2022]
Abstract
Conventional sample preparation for antibody disulfide mapping often requires relatively long digestion time (from several hours to overnight) and relatively high endoproteinase concentration. These conditions are typically necessitated by the fact that antibody molecules are not sufficiently denatured under non-reduced conditions and chaotropic agents are used during digestion to achieve optimal denaturation. Disulfide scrambling can occur as artifacts of digestion as proteins are incubated for extended periods, often at neutral to slightly alkaline pH conditions. Shortening digestion time and lowering the pH during digestion frequently result in incomplete peptide cleavages or variable recoveries. Here, we report the development of a fast and efficient non-reduced Lys-C digestion method based on pressure cycling technology (PCT) and its application in determining disulfide-linkages in monoclonal antibodies (mAbs). Conditions were optimized to ensure complete digestion of the mAb with minimal sample preparation-related disulfide scrambling. The PCT-based method was able to generate up to 10-fold signal increase for some disulfide peptides in a 1h Lys-C digestion compared to the conventional bench-top digestion method. As a result of the shorter digestion time, disulfide scrambling that is seen as a major assay artifact of the conventional method was reduced to less than 0.05% in tested molecules. The results show that the PCT-based method offers fast digestion in a shorter time for all the mAbs tested.
Collapse
Affiliation(s)
- Ying Cheng
- Protein Analytical Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
| | - Yonghong Chen
- Protein Analytical Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Christopher Yu
- Protein Analytical Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| |
Collapse
|
37
|
Kita A, Ponniah G, Nowak C, Liu H. Characterization of Cysteinylation and Trisulfide Bonds in a Recombinant Monoclonal Antibody. Anal Chem 2016; 88:5430-7. [DOI: 10.1021/acs.analchem.6b00822] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Adriana Kita
- Product Characterization, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Gomathinayagam Ponniah
- Product Characterization, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Christine Nowak
- Product Characterization, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Hongcheng Liu
- Product Characterization, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| |
Collapse
|
38
|
Chandrasekhar S, Moorthy BS, Xie R, Topp EM. Thiol-Disulfide Exchange in Human Growth Hormone. Pharm Res 2016; 33:1370-82. [PMID: 26887678 DOI: 10.1007/s11095-016-1879-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Accepted: 02/11/2016] [Indexed: 12/20/2022]
Abstract
PURPOSE Thiol-disulfide exchange was monitored in recombinant human growth hormone (hGH) and in model tryptic peptides derived from hGH to investigate the effects of higher-order structure on the reaction. METHODS Different free thiol-containing peptides, varying in length and amino acid sequence, were used to initiate the reaction at pH 7.0 and 37°C in hGH. Protein samples were digested with trypsin and analyzed for native disulfides, scrambled disulfides and free thiols using LC/MS. The loss of native disulfide and disulfide exchange was compared with model peptides derived from hGH. RESULTS Loss of native disulfide in cyclic (cT20-T21) and linear peptides (T20-T21pep) derived from the C-terminal hGH disulfide during the first 60 min of reaction was greater than loss of the C-terminal disulfide in hGH itself. Of the thiols tested, glutathione (GSH) was the most reactive, forming the highest percentage of mixed disulfides in intact hGH and in the model peptides. At longer reaction times (>240 min), native disulfides in both hGH and cT20-T21 were regenerated. The fastest rates of regeneration were observed for Cys and the di- or tripeptide containing an Arg residue adjacent to Cys, suggesting that they may be useful in refolding. CONCLUSIONS Thiol-disulfide exchange reactions in hGH and related model peptides were influenced by higher order structure, by the size of the thiol reactant and by an Arg residue adjacent to Cys in the thiol reactant. Reduction of disulfide bonds in hGH did not affect higher order structure as measured by CD and HDX-MS.
Collapse
Affiliation(s)
- Saradha Chandrasekhar
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, Room 124D, West Lafayette, Indiana, 47901-2091, USA
| | - Balakrishnan S Moorthy
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, Room 124D, West Lafayette, Indiana, 47901-2091, USA
| | - Ruichao Xie
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, Room 124D, West Lafayette, Indiana, 47901-2091, USA
| | - Elizabeth M Topp
- Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, Room 124D, West Lafayette, Indiana, 47901-2091, USA.
| |
Collapse
|
39
|
Bhuckory S, Mattera L, Wegner KD, Qiu X, Wu YT, Charbonnière LJ, Reiss P, Hildebrandt N. Direct conjugation of antibodies to the ZnS shell of quantum dots for FRET immunoassays with low picomolar detection limits. Chem Commun (Camb) 2016; 52:14423-14425. [DOI: 10.1039/c6cc08835j] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Direct conjugation of IgG, F(ab′)2, and Fab antibodies to the ZnS shells of penicillamine-coated quantum dots for high-sensitivity FRET biosensing.
Collapse
Affiliation(s)
- S. Bhuckory
- NanoBioPhotonics (nanofret.com)
- Institute for Integrative Biology of the Cell (I2BC)
- Université Paris-Saclay
- Université Paris-Sud
- CNRS
| | - L. Mattera
- Univ. Grenoble Alpes
- INAC-SyMMES
- 38054 Grenoble Cedex 9
- France
- CEA
| | - K. D. Wegner
- NanoBioPhotonics (nanofret.com)
- Institute for Integrative Biology of the Cell (I2BC)
- Université Paris-Saclay
- Université Paris-Sud
- CNRS
| | - X. Qiu
- NanoBioPhotonics (nanofret.com)
- Institute for Integrative Biology of the Cell (I2BC)
- Université Paris-Saclay
- Université Paris-Sud
- CNRS
| | - Y.-T. Wu
- NanoBioPhotonics (nanofret.com)
- Institute for Integrative Biology of the Cell (I2BC)
- Université Paris-Saclay
- Université Paris-Sud
- CNRS
| | - L. J. Charbonnière
- Institut Pluridisciplinaire Hubert Curien (IPHC)
- UMR 7178 CNRS/Université de Strasbourg
- Laboratoire d’Ingénierie Moléculaire Appliquée à l’Analyse (LIMAA)
- ECPM
- 67087 Strasbourg Cedex 2
| | - P. Reiss
- Univ. Grenoble Alpes
- INAC-SyMMES
- 38054 Grenoble Cedex 9
- France
- CEA
| | - N. Hildebrandt
- NanoBioPhotonics (nanofret.com)
- Institute for Integrative Biology of the Cell (I2BC)
- Université Paris-Saclay
- Université Paris-Sud
- CNRS
| |
Collapse
|
40
|
Pang Y, Wang WH, Reid GE, Hunt DF, Bruening ML. Pepsin-Containing Membranes for Controlled Monoclonal Antibody Digestion Prior to Mass Spectrometry Analysis. Anal Chem 2015; 87:10942-9. [PMID: 26455365 DOI: 10.1021/acs.analchem.5b02739] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Monoclonal antibodies (mAbs) are the fastest growing class of therapeutic drugs, because of their high specificities to target cells. Facile analysis of therapeutic mAbs and their post-translational modifications (PTMs) is essential for quality control, and mass spectrometry (MS) is the most powerful tool for antibody characterization. This study uses pepsin-containing nylon membranes as controlled proteolysis reactors for mAb digestion prior to ultrahigh-resolution Orbitrap MS analysis. Variation of the residence times (from 3 ms to 3 s) of antibody solutions in the membranes yields "bottom-up" (1-2 kDa) to "middle-down" (5-15 kDa) peptide sizes within less than 10 min. These peptides cover the entire sequences of Trastuzumab and a Waters antibody, and a proteolytic peptide comprised of 140 amino acids from the Waters antibody contains all three complementarity determining regions on the light chain. This work compares the performance of "bottom-up" (in-solution tryptic digestion), "top-down" (intact protein fragmentation), and "middle-down" (in-membrane digestion) analysis of an antibody light chain. Data from tandem MS show 99%, 55%, and 99% bond cleavage for "bottom-up", "top-down", and "middle-down" analyses, respectively. In-membrane digestion also facilitates detection of PTMs such as oxidation, deamidation, N-terminal pyroglutamic acid formation, and glycosylation. Compared to "bottom-up" and "top-down" approaches for antibody characterization, in-membrane digestion uses minimal sample preparation time, and this technique also yields high peptide and sequence coverage for the identification of PTMs.
Collapse
Affiliation(s)
- Yongle Pang
- Department of Chemistry, Michigan State University , East Lansing, Michigan 48824, United States
| | - Wei-Han Wang
- Department of Chemistry, University of Virginia , Charlottesville, Virginia 22904, United States
| | - Gavin E Reid
- School of Chemistry, Department of Biochemistry and Molecular Biology, Bio21 Molecular Science & Biotechnology Institute, The University of Melbourne , Parkville, Victoria 3010, Australia
| | - Donald F Hunt
- Department of Chemistry, University of Virginia , Charlottesville, Virginia 22904, United States.,Department of Pathology, Health Sciences Center, University of Virginia , Charlottesville, Virginia 22908, United States
| | - Merlin L Bruening
- Department of Chemistry, Michigan State University , East Lansing, Michigan 48824, United States
| |
Collapse
|
41
|
Pindrus M, Shire SJ, Kelley RF, Demeule B, Wong R, Xu Y, Yadav S. Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions. Mol Pharm 2015; 12:3896-907. [PMID: 26407030 DOI: 10.1021/acs.molpharmaceut.5b00336] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The purpose of this work was to elucidate the molecular interactions leading to monoclonal antibody self-association and precipitation and utilize biophysical measurements to predict solubility behavior at high protein concentration. Two monoclonal antibodies (mAb-G and mAb-R) binding to overlapping epitopes were investigated. Precipitation of mAb-G solutions was most prominent at high ionic strength conditions and demonstrated strong dependence on ionic strength, as well as slight dependence on solution pH. At similar conditions no precipitation was observed for mAb-R solutions. Intermolecular interactions (interaction parameter, kD) related well with high concentration solubility behavior of both antibodies. Upon increasing buffer ionic strength, interactions of mAb-R tended to weaken, while those of mAb-G became more attractive. To investigate the role of amino acid sequence on precipitation behavior, mutants were designed by substituting the CDR of mAb-R into the mAb-G framework (GM-1) or deleting two hydrophobic residues in the CDR of mAb-G (GM-2). No precipitation was observed at high ionic strength for either mutant. The molecular interactions of mutants were similar in magnitude to those of mAb-R. The results suggest that presence of hydrophobic groups in the CDR of mAb-G may be responsible for compromising its solubility at high ionic strength conditions since deleting these residues mitigated the solubility issue.
Collapse
Affiliation(s)
- Mariya Pindrus
- Summer Intern from Department of Pharmaceutical Sciences, University of Connecticut , Storrs, Connecticut 06269, United States
| | | | | | | | | | | | | |
Collapse
|
42
|
Characterization of cysteine related variants in an IgG2 antibody by LC–MS with an automated data analysis approach. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 997:30-7. [DOI: 10.1016/j.jchromb.2015.04.035] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 04/21/2015] [Accepted: 04/27/2015] [Indexed: 11/22/2022]
|
43
|
Liu H, Jeong J, Kao YH, Zhang YT. Characterization of free thiol variants of an IgG1 by reversed phase ultra high pressure liquid chromatography coupled with mass spectrometry. J Pharm Biomed Anal 2015; 109:142-9. [DOI: 10.1016/j.jpba.2015.02.015] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 02/05/2015] [Accepted: 02/08/2015] [Indexed: 11/26/2022]
|
44
|
Ayoub D, Bertaccini D, Diemer H, Wagner-Rousset E, Colas O, Cianférani S, Van Dorsselaer A, Beck A, Schaeffer-Reiss C. Characterization of the N-Terminal Heterogeneities of Monoclonal Antibodies Using In-Gel Charge Derivatization of α-Amines and LC-MS/MS. Anal Chem 2015; 87:3784-90. [DOI: 10.1021/ac504427k] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Daniel Ayoub
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Diego Bertaccini
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Hélène Diemer
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Elsa Wagner-Rousset
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Olivier Colas
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Sarah Cianférani
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Alain Van Dorsselaer
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| | - Alain Beck
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France
| | - Christine Schaeffer-Reiss
- BioOrganic
Mass
Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg, France
- IPHC, CNRS,
UMR7178, 67087 Strasbourg, France
| |
Collapse
|
45
|
Moorthy BS, Xie B, Moussa EM, Iyer LK, Chandrasekhar S, Panchal JP, Topp EM. Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies. BIOBETTERS 2015. [DOI: 10.1007/978-1-4939-2543-8_8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
46
|
Michels DA, Ip AY, Dillon TM, Brorson K, Lute S, Chavez B, Prentice KM, Brady LJ, Miller KJ. Separation Methods and Orthogonal Techniques. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
- David A. Michels
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Anna Y. Ip
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Thomas M. Dillon
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Kurt Brorson
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Scott Lute
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Brittany Chavez
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Ken M. Prentice
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Lowell J. Brady
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Karen J. Miller
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| |
Collapse
|
47
|
Liu H, Ponniah G, Zhang HM, Nowak C, Neill A, Gonzalez-Lopez N, Patel R, Cheng G, Kita AZ, Andrien B. In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs 2014; 6:1145-54. [PMID: 25517300 DOI: 10.4161/mabs.29883] [Citation(s) in RCA: 119] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Tremendous knowledge has been gained in the understanding of various modifications of IgG antibodies, driven mainly by the fact that antibodies are one of the most important groups of therapeutic molecules and because of the development of advanced analytical techniques. Recombinant monoclonal antibody (mAb) therapeutics expressed in mammalian cell lines and endogenous IgG molecules secreted by B cells in the human body share some modifications, but each have some unique modifications. Modifications that are common to recombinant mAb and endogenous IgG molecules are considered to pose a lower risk of immunogenicity. On the other hand, modifications that are unique to recombinant mAbs could potentially pose higher risk. The focus of this review is the comparison of frequently observed modifications of recombinant monoclonal antibodies to those of endogenous IgG molecules.
Collapse
Affiliation(s)
- Hongcheng Liu
- a Protein Characterization; Alexion Pharmaceuticals Inc .; Cheshire , CT USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Pérez Medina Martínez V, Abad-Javier ME, Romero-Díaz AJ, Villaseñor-Ortega F, Pérez NO, Flores-Ortiz LF, Medina-Rivero E. Comparability of a three-dimensional structure in biopharmaceuticals using spectroscopic methods. JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY 2014; 2014:950598. [PMID: 24963443 PMCID: PMC4055658 DOI: 10.1155/2014/950598] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2014] [Accepted: 04/23/2014] [Indexed: 06/03/2023]
Abstract
Protein structure depends on weak interactions and covalent bonds, like disulfide bridges, established according to the environmental conditions. Here, we present the validation of two spectroscopic methodologies for the measurement of free and unoxidized thiols, as an attribute of structural integrity, using 5,5'-dithionitrobenzoic acid (DTNB) and DyLight Maleimide (DLM) as derivatizing agents. These methods were used to compare Rituximab and Etanercept products from different manufacturers. Physicochemical comparability was demonstrated for Rituximab products as DTNB showed no statistical differences under native, denaturing, and denaturing-reducing conditions, with Student's t-test P values of 0.6233, 0.4022, and 0.1475, respectively. While for Etanercept products no statistical differences were observed under native (P = 0.0758) and denaturing conditions (P = 0.2450), denaturing-reducing conditions revealed cysteine contents of 98% and 101%, towards the theoretical value of 58, for the evaluated products from different Etanercept manufacturers. DLM supported equality between Rituximab products under native (P = 0.7499) and denaturing conditions (P = 0.8027), but showed statistical differences among Etanercept products under native conditions (P < 0.001). DLM suggested that Infinitam has fewer exposed thiols than Enbrel, although DTNB method, circular dichroism (CD), fluorescence (TCSPC), and activity (TNF α neutralization) showed no differences. Overall, this data revealed the capabilities and drawbacks of each thiol quantification technique and their correlation with protein structure.
Collapse
Affiliation(s)
- Víctor Pérez Medina Martínez
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de Carreteras Acatzingo-Zumpahuacán S/N, Tenancingo, 52400 Mexico, MEX, Mexico
| | - Mario E. Abad-Javier
- Departamento de Ingeniería Bioquímica, Instituto Tecnológico de Celaya, Avenida Tecnológico y Antonio García Cubas S/N, 38010 Celaya, GTO, Mexico
| | - Alexis J. Romero-Díaz
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de Carreteras Acatzingo-Zumpahuacán S/N, Tenancingo, 52400 Mexico, MEX, Mexico
| | - Francisco Villaseñor-Ortega
- Departamento de Ingeniería Bioquímica, Instituto Tecnológico de Celaya, Avenida Tecnológico y Antonio García Cubas S/N, 38010 Celaya, GTO, Mexico
| | - Néstor O. Pérez
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de Carreteras Acatzingo-Zumpahuacán S/N, Tenancingo, 52400 Mexico, MEX, Mexico
| | - Luis F. Flores-Ortiz
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de Carreteras Acatzingo-Zumpahuacán S/N, Tenancingo, 52400 Mexico, MEX, Mexico
| | - Emilio Medina-Rivero
- Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de Carreteras Acatzingo-Zumpahuacán S/N, Tenancingo, 52400 Mexico, MEX, Mexico
| |
Collapse
|
49
|
Yang Y, Stella C, Wang W, Schöneich C, Gennaro L. Characterization of Oxidative Carbonylation on Recombinant Monoclonal Antibodies. Anal Chem 2014; 86:4799-806. [DOI: 10.1021/ac4039866] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
| | - Cinzia Stella
- Eurofins Lancaster Laboratories, Inc., 2425 New Holland Pike, P.O. Box 12425, Lancaster, Pennsylvania 17605, United States
| | | | - Christian Schöneich
- Department
of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States
| | | |
Collapse
|
50
|
Sandra K, Vandenheede I, Sandra P. Modern chromatographic and mass spectrometric techniques for protein biopharmaceutical characterization. J Chromatogr A 2014; 1335:81-103. [DOI: 10.1016/j.chroma.2013.11.057] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Revised: 11/27/2013] [Accepted: 11/29/2013] [Indexed: 10/25/2022]
|